Dcf Advisers, LLC Intra Cellular Therapies, Inc. Transaction History

Dcf Advisers, LLC

$185 Million
Q2 2024

A detailed history of Dcf Advisers, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Dcf Advisers, LLC holds 100,507 shares of ITCI stock, worth $8.59 Million. This represents 3.72% of its overall portfolio holdings.

Number of Shares

100,507

Previous 96,857 3.77%

Holding current value

$8.59 Million

Previous $6.7 Million 2.7%

% of portfolio

3.72%

Previous 3.4%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$64.76 - $79.84 $236,374 - $291,416	3,650 Added 3.77%	100,507 $6.88 Million
Q4 2023 Feb 13, 2024	SELL	$46.37 - $73.65 $477,611 - $758,595	-10,300 Reduced 9.61%	96,857 $6.94 Million
Q2 2023 Aug 09, 2023	SELL	$54.67 - $66.44 $625,588 - $760,272	-11,443 Reduced 9.65%	107,157 $6.79 Million
Q1 2023 May 15, 2023	SELL	$43.8 - $56.99 $1.65 Million - $2.15 Million	-37,650 Reduced 24.1%	118,600 $6.42 Million
Q4 2022 Feb 13, 2023	SELL	$44.07 - $54.45 $429,638 - $530,833	-9,749 Reduced 5.87%	156,250 $8.27 Million
Q3 2022 Nov 14, 2022	SELL	$42.7 - $59.99 $1.73 Million - $2.43 Million	-40,589 Reduced 19.65%	165,999 $7.72 Million
Q2 2022 Aug 11, 2022	SELL	$43.0 - $65.64 $1.37 Million - $2.09 Million	-31,912 Reduced 13.38%	206,588 $11.8 Million
Q1 2022 May 13, 2022	SELL	$38.74 - $62.09 $4.67 Million - $7.48 Million	-120,500 Reduced 33.57%	238,500 $14.6 Million
Q4 2021 Feb 10, 2022	SELL	$35.2 - $53.42 $704,000 - $1.07 Million	-20,000 Reduced 5.28%	359,000 $18.8 Million
Q3 2021 Nov 15, 2021	BUY	$28.72 - $42.49 $114,880 - $169,960	4,000 Added 1.07%	379,000 $14.1 Million
Q2 2021 Aug 13, 2021	SELL	$29.3 - $44.5 $1.45 Million - $2.2 Million	-49,500 Reduced 11.66%	375,000 $15.3 Million
Q4 2020 Feb 12, 2021	SELL	$23.34 - $32.22 $58,350 - $80,550	-2,500 Reduced 0.59%	424,500 $13.5 Million
Q3 2020 Nov 13, 2020	BUY	$17.61 - $31.86 $26,415 - $47,790	1,500 Added 0.35%	427,000 $11 Million
Q2 2020 Aug 13, 2020	SELL	$14.35 - $26.64 $100,450 - $186,480	-7,000 Reduced 1.62%	425,500 $10.9 Million
Q1 2020 May 12, 2020	SELL	$12.31 - $33.12 $437,903 - $1.18 Million	-35,573 Reduced 7.6%	432,500 $6.65 Million
Q4 2019 Feb 12, 2020	BUY	$7.26 - $38.49 $3.4 Million - $18 Million	468,073 New	468,073 $16.1 Million

Others Institutions Holding ITCI

# of Institutions

398

Shares Held

87.5M

Call Options Held

309K

Put Options Held

302K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.07B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dcf Advisers, LLC with notifications on news.

Account